Cytokinetics Receives Revised Rating from UBS Analyst Downgraded to Neutral with Raised Price Target
On January 24, 2024, Cytokinetics (NASDAQ: CYTK) received a revised rating from UBS analyst Ashwani Verma. Verma downgraded the stock ...
Tag: CYTK
Cytokinetics Faces Declining Revenue and Investor Concerns Amidst Decreased Holdings
On August 20, 2023, it was reported that Russell Investments Group Ltd. has reduced its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) ...
Barclays PLC Trims Holdings in Cytokinetics Despite Disappointing Quarterly Earnings
In a recent disclosure with the Securities and Exchange Commission, Barclays PLC revealed that it has trimmed its holdings in ...
Acquisition by Stonnington Group LLC Highlights Growing Confidence in Cytokinetics and Promising Future of Biopharmaceutical Industry
On June 26, 2023, the Securities & Exchange Commission disclosed that Stonnington Group LLC had acquired a new position in ...
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
-
NextGen Healthcare Charts Course for Behavioral Health Transformation
-
Regulatory Shift Sparks Potential Breakthrough for DeFi Technologies
